494 related articles for article (PubMed ID: 19318552)
41. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
[TBL] [Abstract][Full Text] [Related]
42. Both Notch1 and Notch2 contribute to the regulation of melanocyte homeostasis.
Kumano K; Masuda S; Sata M; Saito T; Lee SY; Sakata-Yanagimoto M; Tomita T; Iwatsubo T; Natsugari H; Kurokawa M; Ogawa S; Chiba S
Pigment Cell Melanoma Res; 2008 Feb; 21(1):70-8. PubMed ID: 18353145
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
44. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model.
Masuda S; Kumano K; Suzuki T; Tomita T; Iwatsubo T; Natsugari H; Tojo A; Shibutani M; Mitsumori K; Hanazono Y; Ogawa S; Kurokawa M; Chiba S
Cancer Sci; 2009 Dec; 100(12):2444-50. PubMed ID: 19775286
[TBL] [Abstract][Full Text] [Related]
45. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
[TBL] [Abstract][Full Text] [Related]
46. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
47. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
48. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
[TBL] [Abstract][Full Text] [Related]
49. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
50. [Inhibitory effects of gamma secretase inhibitor on human multiple myeloma xenograft mouse model].
Liu QQ; Liu JL; Guo DM; Teng QL
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):794-7. PubMed ID: 24103879
[TBL] [Abstract][Full Text] [Related]
51. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
[TBL] [Abstract][Full Text] [Related]
52. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
53. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.
Kumar V; Palermo R; Talora C; Campese AF; Checquolo S; Bellavia D; Tottone L; Testa G; Miele E; Indraccolo S; Amadori A; Ferretti E; Gulino A; Vacca A; Screpanti I
Leukemia; 2014 Dec; 28(12):2324-35. PubMed ID: 24727676
[TBL] [Abstract][Full Text] [Related]
54. Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein.
Li GH; Fan YZ; Liu XW; Zhang BF; Yin DD; He F; Huang SY; Kang ZJ; Xu H; Liu Q; Wu YL; Niu XL; Zhang L; Liu L; Hao MW; Han H; Liang YM
Mol Cell Biochem; 2010 Jul; 340(1-2):7-14. PubMed ID: 20157766
[TBL] [Abstract][Full Text] [Related]
55. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
[TBL] [Abstract][Full Text] [Related]
56. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
[TBL] [Abstract][Full Text] [Related]
57. Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.
Yoon SO; Zapata MC; Singh A; Jo WS; Spencer N; Choi YS
Apoptosis; 2014 Nov; 19(11):1616-26. PubMed ID: 25156146
[TBL] [Abstract][Full Text] [Related]
58. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
59. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
[TBL] [Abstract][Full Text] [Related]
60. Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach?
Kamstrup MR; Biskup E; Gniadecki R
Br J Dermatol; 2010 Oct; 163(4):781-8. PubMed ID: 20560956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]